-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Maybe the academicians "went down", the domestic basic research capacity was improved, and they saw the signs!
"Shenzhen extended an olive branch to me, and I numbly submitted my resignation to Princeton University
.
" The official announcement of 45-year-old scientist Yan Ning shook all walks of life
.
Coming
back.
Next, Yan Ning will do something that the domestic medical and scientific circles are looking forward to: serve as the founding president of the Shenzhen Academy of Medical Sciences, lead clinical, transformation and industrialization work, and promote the innovation
of scientific research models.
"I will assist Shenzhen to create a new type of R&D institution integrating scientific research, translation, student training, funding and other functions - Shenzhen Academy of Medical Sciences, challenging biomedical problems and making truly original breakthroughs
.
"
In March 2021, the Shenzhen Municipal People's Government issued the "Construction Plan of Shenzhen Academy of Medical Sciences", proposing that the institution will focus on the prevention and treatment of major diseases, international cutting-edge medical technology, and sustainable health research fields, mainly carry out applied basic research, clinical and translational research, and public health research, and promote the innovation of the whole chain of research transformation, engineering and industrialization, benchmarking against the world's top medical research and funding institutions
such as the US NIH.
The Shenzhen Academy of Medical Sciences focuses on the existing pain points
in the entire pharmaceutical industry.
Yan Ning's wish also "resonates"
with the desire of the pharmaceutical industry.
The real development of China's innovative drugs has only been four or five years, and there is still a lack of original innovation, and the shackles of basic scientific research need to be solved
.
Yan Ning said: "Basic research is inseparable from medicine and medicine, which is a major trend in the modern pharmaceutical industry, and from the hospital bed to the laboratory, to the pharmaceutical company, and back to the hospital bed, it is also an important mission
of Shenzhen Medical Academy to open up this end-to-end smooth connection.
" ”
Shenzhen Academy of Medical Sciences is the first city-level medical academy in China, and there is no doubt that the institution will give birth to a new soil for domestic basic research.
In recent years, a large number of top scientific research talents have returned to China to cultivate and look for original innovation, and academicians such as Shi Yigong and Wang Xiaodong have "gone down" to open start-up companies, which has urgent needs and practical significance
.
What can their "sorties" bring? The entire pharmaceutical community is looking forward
to it.
01 Domestic basic research is weak, and bottlenecks need to be broken urgently
Domestic basic research is weak, and bottlenecks need to be broken urgentlyUniversities are "not confident", scientists "compromise", entrepreneurs "self-deceive" .
.
.
Standing in the entire pharmaceutical industry, everyone has their own thoughts and hesitations, it is difficult to open up the pharmaceutical innovation industry chain, and it is difficult to implement the transformation of innovation achievements
.
Compared with the international community, the overall level of pharmaceutical innovation in China still lags behind the global leading level, the proportion of basic research funds is low, the number of top scientific research institutions is limited, and the field of forward-looking scientific research and innovation needs to be broken through
.
At present, China's innovation resources in the field of biomedicine are mainly concentrated in the pharmaceutical industry, and the transformation of basic research/R&D achievements in universities, hospitals and scientific research institutions is relatively weak
.
McKinsey Global Managing Partner Wang Jin previously said at the 2021 Inspiration Conference that in terms of capital investment, although China's total R&D investment has ranked second in the world in recent years, when the use of R&D funds at different stages is broken down, it is found that China has a structural weakness
in the basic research stage.
China's share of basic research in R&D funding is only 6%, far lower than the average of
15% in Japan, South Korea, the United States, the United Kingdom, and Switzerland.
At the same time, it also reflects the insufficient
support for the incubation of basic research results by investment.
Basic research is the source of innovation at the forefront of the pharmaceutical R&D value chain, through disease mechanism research, target discovery, target identification and verification, drug screening and optimization and other translational research, to achieve the industrial transformation of scientific and technological achievements and provide an innovation engine
for pharmaceutical R&D.
However, in the view of Liu Que, CMO of Yachuang Pharmaceutical: "Domestic basic research is still weak, and there are many projects to follow, always follow the trend, and over time will be led by others, which forms a vicious circle
.
" In fact, these problems can be avoided from the perspective of enterprises, domestic pharmaceutical companies can cooperate with foreign enterprises or research institutions to develop new targets, for some small enterprises, they can also cooperate with domestic research, which is also a good way
.
”
Chen Xiaomin, COO of Amador Biologics, also holds the same view, she believes that in recent years, a series of policies such as drug review reform in China are beneficial, China is building a relatively complete pharmaceutical innovation ecosystem, and new drug research and development has made a qualitative leap
.
In quantitative terms, China's contribution to global innovation is second only to that of the United States
.
"But what needs to be faced squarely is that the original innovation and basic research capabilities still need to be strengthened
.
"
So how to improve the strength of basic research? This requires the establishment of talent exchange channels between academia, medicine and industry, linking basic research, clinical needs and commercial applications, so the return of Yan Ning, Shi Yigong and other academicians from academia to industry value is highlighted
.
It was also said that in order to optimize the way of public investment in basic research and improve the efficiency of fund management and use, the support for basic research also needs to be led by national special funds, appropriately increase early research investment, to fund the effective exploration of new mechanisms and new targets, and truly balance a research direction
of differentiated improvement and breakthrough innovation.
The Shenzhen Medical Academy where Yan Ning is going has a diversified fund-raising mechanism
composed of government funding, social investment, and transformation of income.
Through the establishment of the "Shenzhen Medical Research Special Fund", the government supports the Shenzhen Academy of Medical Sciences to carry out research on projects inside and outside the hospital
.
02 Academicians "go down the mountain", the imagination space of scientific research and industry cooperation
Academicians "go down the mountain", the imagination space of scientific research and industry cooperationStarting from Tsinghua University, he went to serve in an Ivy League university, and Yan Ning was full of honors: the youngest professor and doctoral supervisor of Tsinghua University School of Medicine, leading a team with an average age of less than 30 years to overcome 50 years of unsolved scientific problems in the field of membrane protein research, foreign academician of the National Academy of Sciences.
.
.
Yan Ning's own "hardcore" strength will continue to be exerted in China, and what kind of spark will collide with the Shenzhen Medical Institute? It's exciting
.
In fact, in addition to the return of "Yan Ning", academicians have successively "descended the mountain", realizing the phenomenon of strong cooperation between scientific research and industry has become more and more popular in recent years, and more and more top scientists have begun to participate in the process of basic research transformation, achieve source innovation, and challenge transformation problems
.
Most of them are active in the front line of new drug research and development companies, on the one hand, they participate in the establishment of a pharmaceutical company as co-founders; On the other hand, he joins a pharmaceutical company
by way of employment.
According to the incomplete statistics of E drug managers, the pharmaceutical companies founded by academicians "down the mountain" are (the following is sorted according to the time of establishment of the company):
According to the incomplete statistics of E drug managers, the pharmaceutical companies founded by academicians "down the mountain" are (the following is sorted according to the time of establishment of the company):Wang Xiaodong - BeiGene + Viterylon
Wang Xiaodong is the first person in the mainland to obtain an academician of the American Academy of Sciences after the reform and opening up, and is also a foreign academician of the Chinese Academy of
Sciences.
His research focuses on the biochemical pathways and biochemical processes of apoptosis, and he founded the Beijing Institute of Biological Sciences of the Chinese Academy of Sciences, where he served as its first and second directors, and later BeiGene and Viterellon
respectively.
In 2010, BeiGene was born, the first pharmaceutical company to be listed on the US, Hong Kong and STAR boards, and the first batch of biotech
to enter commercialization.
In 2018, Wang Xiaodong and Zhang Zhiyuan, senior researcher of Beisheng Institute and director of the Technology Transformation Center, co-founded Sironax, a global biopharmaceutical company focusing on the research and development of first-in-class chemical drugs, focusing on neurodegenerative diseases and inflammatory diseases, mainly based on the basic research of Wang Xiaodong's laboratory on the mechanism of apoptosis.
and the ability
of the laboratories of Xiaodong Wang and Zhiyuan Zhang to develop small molecule drugs that target the mechanism of apoptosis.
At present, the clinical trial application of Viterellon's first product RIP1 inhibitor has been accepted
by the NMPA.
Shi Yigong - InnoCare Care
Shi Yigong is quite famous in the industry, and has successively served as the vice president of Tsinghua University and the founding president of Westlake University, and Yan Ning studied under Shi Yigong
.
At present, Shi Yigong holds many titles
such as academician of the Chinese Academy of Sciences, chair professor of the School of Life Sciences of Tsinghua University, foreign academician of the American Academy of Arts and Sciences, foreign academician of the National Academy of Sciences, and foreign member of the European Molecular Biology Organization (EMBO).
InnoCare was born in 2015 by Shi Yigong and Cui Jisong
.
At that time, the drug review reform had just begun, and the domestic emphasis on new drug research and development had risen to the strategic level
.
InnoCare was born, and its website has expressed its vision from the beginning - to provide advanced and innovative drugs
to patients around the world who are fighting cancer and immune system diseases.
At present, InnoCare has achieved A+H dual listing
.
Dong Chen - Xinkanghe Biomedicine, Pinoji Biotechnology
Dong Chen is a world-renowned immunologist, elected as an academician of the Chinese Academy of Sciences in 2019, former professor and dean of Tsinghua University School of Medicine, director of the Institute of Immunology of Tsinghua University, project leader of the National Key Research and Development Precision Medicine Program, head of the "Inflammatory Biology and Disease" innovation group of the National Natural Science Foundation of China, and director of the Beijing Key Laboratory of
Immunology Research on Chronic Diseases.
He is currently the founding director
of Shanghai Institute of Immunotherapy Innovation.
As early as 2015, Dong Chen founded Xinkanghe Biopharmaceutical, and the company's R&D team relied on the core technology platform related to innovative antibody research and development to rapidly promote various products under development, focusing on the research and development
of innovative antibody drugs for tumor immunity and autoimmunity.
Following Xin Kanghe, in November 2021, Dong Chen co-founded another biotech, Pinoci Biologics, together with Hillhouse Venture Capital, Chende Capital and other institutions, focusing on solid tumor cell therapy, and has raised hundreds of millions of yuan
since its establishment.
Sun Yongkui - Life of the Force
Founded in November 2016 by Sun Yongkui, Force Life is a biotechnology company
focusing on the research and development of a new generation of innovative drugs for tumor targeting and tumor immunomodulation, with a global equity layout.
Founder, Chairman and CEO Sun Yongkui in 2016
He was elected as an academician of the National Academy of Engineering, and has worked for Merck for more than 20 years, with very rich experience
in new drug research and development and business development.
In August 2021, Force Life completed a financing of
US$100 million.
Xie Xiaoliang - Dan Order Biology
Xie Xiaoliang bears the halo of academicians of the four Chinese and American academies, which are academicians of the US National Academy of Sciences, academicians of the US National Academy of Medicine, academicians of the American Academy of Arts and Sciences, and foreign academicians of the Chinese Academy of Sciences
.
In 2014, Xie Xiaoliang and his team achieved the birth
of the world's first "MALBAC baby".
In 2015, Xie Xiaoliang won the Alberni Biomedical Award, a heavyweight biomedical award in the United States, becoming the first Chinese winner
of the award.
Many scientists who won the prize later won the Nobel Prize, so they are also known as "the closest Chinese to the Nobel Prize"
.
2018
In that year, Xie Xiaoliang officially returned to his alma mater Peking University full-time to teach
.
In June 2020, Xie Xiaoliang, as a co-founder, founded Danxu Biologics, which is committed to the research and development of antibody drugs using the single-cell sequencing technology platform, and continuously promotes innovative drug research for various indications, including infectious diseases and cancer, and develops good drugs
that Chinese people can afford.
Shao Feng - Yanming Biology
Shao Feng is the deputy academic director and senior researcher of the Beijing Institute of Biological Sciences, and was elected as an academician
of the Chinese Academy of Sciences in 2015.
In 2020, Shao Feng and Deng Tianjing co-founded Yanming Biotechnology, the founder and chairman of Shao Feng, to develop the first-in-class cell pyrotic drug
.
Subsequently, a breakthrough was made in the development of a new drug molecule project for the Gasdermin family protein to inhibit cell pyrosis, and it was the world's first inhibitor of specific needle Gasdermin protein, achieving the world's leading new drug research and development
from 0-1.
In addition, more and more academicians are active in the front line, joining pharmaceutical companies and taking up important positions
.
For example, Haixiang Pharmaceutical hired Chen Fen'er, an academician of the Chinese Academy of Engineering, as the chief scientist to accelerate the company's scientific and technological innovation and product upgrading; Yantai Pharmaceutical appointed Chen Hongmin, an academician of the American Academy of Engineering, as the president and head of R&D of the American company; Guangzhou Pharmaceutical Group appointed Liu Liang, academician of the Chinese Academy of Engineering, as the chief scientist and honorary president of the General Institute of Guangzhou Pharmaceutical Research.
.
.
.
In addition, there are "first create a company, then be elected academician" medical personnel
.
For example, Wu Yiling, the founder of Yiling Pharmaceutical, was elected as an academician of the Chinese Academy of Engineering in 2009, and Xiao Wei, chairman of Kangyuan Pharmaceutical, was elected as an academician of the Chinese Academy of Engineering in 2021
.
